201
|
|
202
|
Yatabe J, Sanada H, Midorikawa S, Hashimoto S, Watanabe T, Andrews PM, Armando I, Wang X, Felder RA, Jose PA. Effects of decreased renal cortical expression of G protein-coupled receptor kinase 4 and angiotensin type 1 receptors in rats. Hypertens Res 2008; 31:1455-64. [PMID: 18957817 DOI: 10.1291/hypres.31.1455] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abnormalities in renal angiotensin type 1 receptor (AT1R), D1 dopamine receptor (D1R) and G protein-coupled receptor kinase 4 (GRK4) are present in polygenic hypertension. Selective renal reduction of AT1R expression by intrarenal cortical infusion of antisense oligodeoxynucleotides (As-Odns) in conscious, uninephrectomized, sodium-loaded rats decreases proteinuria, normalizes the glomerular sclerosis index (GSI), increases the sodium excretion (UNaV), and modestly increases blood pressure (BP) in spontaneously hypertensive rats (SHR) but not in normotensive Wistar-Kyoto rats (WKY). In contrast, selective renal reduction of GRK4 expression by infusion of GRK4 As-Odns increases UnaV, attenuates the increase in arterial BP with age, and modestly decreases protein excretion in SHR, but not in WKY. In this study, we report that intrarenal cortical infusion of both GRK4 and AT1R As-Odns decreased BP and increased UNaV in SHR; these effects were also noted in WKY to a lesser extent. Infusion of SHR with this combination of As-Odns resulted in a decrease in proteinuria and improvement of GSI similar to those by AT1R As-Odn only. In contrast to the increased circulating angiotensin II and aldosterone levels induced by AT1R As-Odn alone, the combination of As-Odns decreased both, contributing to greater natriuresis and amelioration of hypertension than by GRK4 or AT1R As-Odn only. Our results indicate an interaction between GRK4-regulated receptors and the renin-angiotensin system in the regulation of renal function and BP.
Collapse
Affiliation(s)
- Junichi Yatabe
- Department of Internal Medicine III, Fukushima Medical University School of Medicine, Fukushima, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
203
|
Genetic variation in the KCNMA1 potassium channel α subunit as risk factor for severe essential hypertension and myocardial infarction. J Hypertens 2008; 26:2147-53. [DOI: 10.1097/hjh.0b013e32831103d8] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
204
|
Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VAM, Jones JE, Wang Z, Periasamy A, Lau YS, Soares-da-Silva P, Creswell K, Guillemette G, Sibley DR, Eisner G, Gildea JJ, Felder RA, Jose PA. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J Clin Invest 2008; 118:2180-9. [PMID: 18464932 DOI: 10.1172/jci33637] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2007] [Accepted: 03/19/2008] [Indexed: 12/12/2022] Open
Abstract
Hypertension is a multigenic disorder in which abnormal counterregulation between dopamine and Ang II plays a role. Recent studies suggest that this counterregulation results, at least in part, from regulation of the expression of both the antihypertensive dopamine 5 receptor (D5R) and the prohypertensive Ang II type 1 receptor (AT1R). In this report, we investigated the in vivo and in vitro interaction between these GPCRs. Disruption of the gene encoding D5R in mice increased both blood pressure and AT1R protein expression, and the increase in blood pressure was reversed by AT1R blockade. Activation of D5R increased the degradation of glycosylated AT1R in proteasomes in HEK cells and human renal proximal tubule cells heterologously and endogenously expressing human AT1R and D5R. Confocal microscopy, Förster/fluorescence resonance energy transfer microscopy, and fluorescence lifetime imaging microscopy revealed that activation of D5R initiated ubiquitination of the glycosylated AT1R at the plasma membrane. The regulated degradation of AT1R via a ubiquitin/proteasome pathway by activation of D5R provides what we believe to be a novel mechanism whereby blood pressure can be regulated by the interaction of 2 counterregulatory GPCRs. Our results therefore suggest that treatments for hypertension might be optimized by designing compounds that can target the AT1R and the D5R.
Collapse
Affiliation(s)
- Hewang Li
- Department of Pediatrics, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
205
|
The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 2008; 17:168-73. [PMID: 18277150 DOI: 10.1097/mnh.0b013e3282f521a8] [Citation(s) in RCA: 114] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE OF REVIEW The renin-angiotensin system, traditionally viewed as a circulatory system, has significantly expanded in the last two decades to include independently regulated local systems in several tissues, newly identified active products of angiotensin II, and new receptors and functions of renin-angiotensin system components. In spite of our increased understanding of the renin-angiotensin system, a role of angiotensin II in cardiac hypertrophy, through direct effects on cardiovascular tissue, is still being debated. Here, we address the cardiovascular effects of angiotensin II and the role an intracellular renin-angiotensin system might play. RECENT FINDINGS Recent studies have shown that cardiac myocytes, fibroblasts and vascular smooth muscle cells synthesize angiotensin II intracellularly. Some conditions, such as high glucose, selectively increase intracellular generation and translocation of angiotensin II to the nucleus. Intracellular angiotensin II regulates the expression of angiotensinogen and renin, generating a feedback loop. The first reaction of intracellular angiotensin II synthesis is catalyzed by renin or cathepsin D, depending on the cell type, and chymase, not angiotensin-converting enzyme, catalyzes the second step. SUMMARY These studies suggest that the intracellular renin-angiotensin system is an important component of the local system. Alternative mechanisms of angiotensin II synthesis and action suggest a need for novel therapeutic agents to block the intracellular renin-angiotensin system.
Collapse
|
206
|
Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population. Pharmacogenet Genomics 2008; 18:459-66. [DOI: 10.1097/fpc.0b013e3282f97fb2] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
207
|
Otani H, Otsuka F, Inagaki K, Suzuki J, Miyoshi T, Kano Y, Goto J, Ogura T, Makino H. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008; 149:2816-25. [PMID: 18308844 DOI: 10.1210/en.2007-1476] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Circulating aldosterone concentrations occasionally increase after initial suppression with angiotensin II (Ang II) converting enzyme inhibitors or Ang II type 1 receptor blockers (ARBs), a phenomenon referred to as aldosterone breakthrough. However, the underlying mechanism causing the aldosterone breakthrough remains unknown. Here we investigated whether aldosterone breakthrough occurs in human adrenocortical H295R cells in vitro. We recently reported that bone morphogenetic protein (BMP)-6, which is expressed in adrenocortical cells, enhances Ang II- but not potassium-induced aldosterone production in human adrenocortical cells. Accordingly, we examined the roles of BMP-6 in aldosterone breakthrough induced by long-term treatment with ARB. Ang II stimulated aldosterone production by adrenocortical cells. This Ang II stimulation was blocked by an ARB, candesartan. Interestingly, the candesartan effects on Ang II-induced aldosterone synthesis and CYP11B2 expression were attenuated in a course of candesartan treatment for 15 d. The impairment of candesartan effects on Ang II-induced aldosterone production was also observed in Ang II- or candesartan-pretreated cells. Levels of Ang II type 1 receptor mRNA were not changed by chronic candesartan treatment. However, BMP-6 enhancement of Ang II-induced ERK1/2 signaling was resistant to candesartan. The BMP-6-induced Smad1, -5, and -8 phosphorylation, and BRE-Luc activity was augmented in the presence of Ang II and candesartan in the chronic phase. Chronic Ang II exposure decreased cellular expression levels of BMP-6 and its receptors activin receptor-like kinase-2 and activin type II receptor mRNAs. Cotreatment with candesartan reversed the inhibitory effects of Ang II on the expression levels of these mRNAs. The breakthrough phenomenon was attenuated by neutralization of endogenous BMP-6 and activin receptor-like kinase-2. Collectively, these data suggest that changes in BMP-6 availability and response may be involved in the occurrence of cellular escape from aldosterone suppression under chronic treatment with ARB.
Collapse
Affiliation(s)
- Hiroyuki Otani
- Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama City 700-8558, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
208
|
Abstract
Angiotensin converting enzyme 2 (ACE2) is an important homeostatic component of the renin angiotensin system (RAS). ACE2 both degrades the vasoconstrictor, angiotensin II and generates the potent vasodilator peptide, angiotensin 1–7. These actions counterbalance those of ACE. ACE2 is highly expressed in the healthy kidney, particularly in the proximal tubules, where it colocalizes with ACE and angiotensin receptors. Kidney disease and subtotal nephrectomy is associated with a reduction in renal ACE2 expression, possibly facilitating the damaging effects of angiotensin II in the failing kidney. Acquired or genetic ACE2 deficiency also appears to exacerbate renal damage and albuminuria in experimental models, supporting this hypothesis. ACE2 also has an important role in blood pressure control. Many models of hypertension are associated with reduced ACE2 expression. Although ACE2 KO animals are normotensive, in states associated with activation of the RAS, ACE2 overexpression improves blood pressure control and reduces angiotensin responsiveness.
Collapse
Affiliation(s)
- A Koitka
- Division of Diabetic Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia
| | | | | | | |
Collapse
|
209
|
Gratze P, Dechend R, Stocker C, Park JK, Feldt S, Shagdarsuren E, Wellner M, Gueler F, Rong S, Gross V, Obst M, Plehm R, Alenina N, Zenclussen A, Titze J, Small K, Yokota Y, Zenke M, Luft FC, Muller DN. Novel role for inhibitor of differentiation 2 in the genesis of angiotensin II-induced hypertension. Circulation 2008; 117:2645-56. [PMID: 18474814 DOI: 10.1161/circulationaha.107.760116] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Angiotensin (Ang) II-induced target-organ damage involves innate and acquired immunity. Mice deficient for the helix-loop-helix transcription factor inhibitor of differentiation (Id2(-/-)) lack Langerhans and splenic CD8a+ dendritic cells, have reduced natural killer cells, and have altered CD8 T-cell memory. We tested the hypothesis that an alteration in the number and quality of circulating blood cells caused by Id2 deletion would ameliorate Ang II-induced target-organ damage. METHODS AND RESULTS We used gene-deleted and transgenic mice. We conducted kidney and bone marrow transplants. In contrast to Ang II-infused Id2(+/-), Id2(-/-) mice infused with Ang II remained normotensive and failed to develop albuminuria or renal damage. Bone marrow transplant of Id2(+/-) bone marrow to Id2(-/-) mice did not restore the blunted blood pressure response to Ang II. Transplantation of Id2(-/-) kidneys to Id2(+/-) mice also could not prevent Ang II-induced hypertension and renal damage. We verified the Ang II resistance in Id2(-/-) mice in a model of local tissue Ang II production by crossing hypertensive mice transgenic for rat angiotensinogen with Id2(-/-) or Id2(+/-) mice. Angiotensinogen-transgenic Id2(+/-) mice developed hypertension, albuminuria, and renal injury, whereas angiotensinogen-transgenic Id2(-/-) mice did not. We also found that vascular smooth muscle cells from Id2(-/-) mice showed an antisenescence phenotype. CONCLUSIONS Our bone marrow and kidney transplant experiments suggest that alterations in circulating immune cells or Id2 in the kidney are not responsible for Ang II resistance. The present studies identify a previously undefined role for Id2 in the pathogenesis of Ang II-induced hypertension.
Collapse
Affiliation(s)
- Petra Gratze
- Medical Faculty of the Charité, Experimental and Clinical Research Center, Franz Volhard Clinic, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
210
|
Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med (Berl) 2008; 86:615-21. [PMID: 18414822 DOI: 10.1007/s00109-008-0336-0] [Citation(s) in RCA: 194] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2008] [Revised: 02/26/2008] [Accepted: 02/27/2008] [Indexed: 12/15/2022]
Abstract
Angiotensin (Ang) II is not only generated in the circulation by renin and angiotensin-converting enzyme (ACE) but also is produced locally in numerous organs including kidney, vessels, heart, adrenal gland, eye, testis, and brain. Furthermore, widely distributed mast cells have been shown to be a production site. Local Ang II production process is commonly termed the result of a "tissue" renin-angiotensin system (RAS). Because pharmacological experiments do not easily allow targeting of specific tissues, many novel findings about the functional importance of tissue RAS have been collected from transgenic rodent models. These animals either overexpress or lack RAS components in specific tissues and thereby elucidate their local functions. The data to date show that in most tissues local RAS amplify the actions of circulating Ang II with important implications for physiology and pathophysiology of cardiovascular diseases. This review summarizes the recent findings on the importance of tissue RAS in the most relevant cardiovascular organs.
Collapse
Affiliation(s)
- Michael Bader
- Max-Delbrück-Centrum for Molecular Medicine (MDC), Berlin, Germany.
| | | |
Collapse
|
211
|
Affiliation(s)
- Thomas M Coffman
- Division of Nephrology, Department of Medicine, Duke University and Durham Veterans'Affairs Medical Centers, Durham, NC, USA.
| | | |
Collapse
|
212
|
Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26:381-91. [PMID: 18300843 PMCID: PMC2742362 DOI: 10.1097/hjh.0b013e3282f29876] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Since its first identification in the late 1800s, a variety of etiologies for essential hypertension have been proposed. In this paper we review the primary proposed hypotheses in the context of both the time in which they were proposed as well as the subsequent studies performed over the years. From these various insights, we propose a current paradigm to explain the renal mechanisms underlying the hypertension epidemic today. Specifically, we propose that hypertension is initiated by agents that cause systemic and intrarenal vasoconstriction. Over time intrarenal injury develops with microvascular disease, interstitial T cell and macrophage recruitment with the induction of an autoimmune response, with local angiotensin II formation and oxidant generation. These changes maintain intrarenal vasoconstriction and hypoxia with a change in local vasoconstrictor-vasodilator balance favoring sodium retention. Both genetic and congenital (nephron number) mechanisms have profound influence on this pathway. As blood pressure rises, renal ischemia is ameliorated and sodium balance restored completely (in salt-resistant) or partially (in salt-sensitive) hypertension, but at the expense of a rightward shift in the pressure natriuresis curve and persistent hypertension.
Collapse
Affiliation(s)
- Richard J Johnson
- Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida 32610-0224, USA.
| | | | | | | | | |
Collapse
|
213
|
Abstract
PURPOSE OF REVIEW The renin-angiotensin system plays a key role in the regulation of blood pressure and fluid homeostasis. Owing to its critical contribution to blood pressure control, abnormalities of any component in this system can lead to hypertension and cardiovascular diseases. In this review, we will highlight studies using this approach to uncover new perspectives on the physiology of the renin-angiotensin system. RECENT FINDINGS Over the past decade, application of techniques for manipulating the genome of living animals, including gene targeting through homologous recombination in embryonic stem cells, has provided unique insights into the complex biology of the renin-angiotensin system. Along with advances in understanding functions of the classical components of the system, gene targeting has clarified the functions of newly discovered angiotensin-converting enzyme homologues. SUMMARY Since pharmacological antagonists of the renin-angiotensin system are widely used in clinical medicine, advances in the gene-targeting experiments of the system have helped to clarify the mechanisms of action of these agents and may provide clues for improved approaches for the treatment of hypertension and kidney diseases.
Collapse
|
214
|
Padia SH, Kemp BA, Howell NL, Fournie-Zaluski MC, Roques BP, Carey RM. Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Hypertension 2007; 51:460-5. [PMID: 18158338 DOI: 10.1161/hypertensionaha.107.103242] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In the kidney, angiotensin II (Ang II) is metabolized to angiotensin III (Ang III) by aminopeptidase A (APA). In turn, Ang III is metabolized to angiotensin IV by aminopeptidase N (APN). Renal interstitial (RI) infusion of Ang III, but not Ang II, results in angiotensin type-2 receptor (AT(2)R)-mediated natriuresis. This response is augmented by coinfusion of PC-18, a specific inhibitor of APN. The present study addresses the hypotheses that Ang II conversion to Ang III is critical for the natriuretic response. Sprague-Dawley rats received systemic angiotensin type-1 receptor (AT(1)R) blockade with candesartan (CAND; 0.01 mg/kg/min) for 24 hours before and during the experiment. After a control period, rats received either RI infusion of Ang II or Ang II+PC-18. The contralateral kidney received a RI infusion of vehicle in all rats. Mean arterial pressure (MAP) was monitored, and urinary sodium excretion rate (U(Na)V) was calculated separately from experimental and control kidneys for each period. In contrast to Ang II-infused kidneys, U(Na)V from Ang II+PC-18-infused kidneys increased from a baseline of 0.03+/-0.01 to 0.09+/-0.02 micromol/min (P<0.05). MAP was unchanged by either infusion. RI addition of PD-123319, an AT(2)R antagonist, inhibited the natriuretic response. Furthermore, RI addition of EC-33, a selective APA inhibitor, abolished the natriuretic response to Ang II+PC-18. These data demonstrate that RI addition of PC-18 to Ang II enables natriuresis mediated by the AT(2)R, and that conversion of Ang II to Ang III is critical for this response.
Collapse
Affiliation(s)
- Shetal H Padia
- Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-1414, USA.
| | | | | | | | | | | |
Collapse
|
215
|
Woost PG, Kolb RJ, Chang CH, Finesilver M, Inagami T, Hopfer U. Development of an AT2-deficient proximal tubule cell line for transport studies. In Vitro Cell Dev Biol Anim 2007; 43:352-60. [PMID: 17963016 DOI: 10.1007/s11626-007-9061-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2007] [Accepted: 09/11/2007] [Indexed: 12/22/2022]
Abstract
Angiotensin II is a major regulatory peptide for proximal tubule Na(+) reabsorption acting through two distinct receptor subtypes: AT(1) and AT(2). Physiological or pathological roles of AT(2) have been difficult to unravel because angiotensin II can affect Na(+) transport either directly via AT(2) on luminal or peritubular plasma membranes of proximal tubule cells or indirectly via the renal vasculature. Furthermore, separate systemic and intratubular renin-angiotensin systems impart considerable complexity to angiotensin's regulation. A transport-competent, proximal tubule cell model that lacks AT(2) is a potentially useful tool to assess cellular angiotensin II regulation. To this end, AT(2)-receptor-deficient mice were bred with an Immortomouse, which harbors the thermolabile immortalization gene SV40 large-T antigen (Tag), and AT(2)-receptor-deficient [AT(2) (-/-)], Tag heterozygous [Tag (+/-)] F(2) offspring were selected for cell line generation. S1 proximal tubule segments were microdissected, and epithelial cell outgrowth was expanded in culture. Cells that formed confluent, electrically resistive monolayers were selected for cryopreservation, and one isolate was extensively characterized for conductance (2 mS/cm(2)), short-circuit current (Isc; 0.2 microA/cm(2)), and proximal tubule-specific Na3(+) - succinate (DeltaIsc = 0.8 microA/cm(2) at 2 mM succinate) and Na3(+) - phosphate cotransport (DeltaIsc = 3 microA/cm(2) at 1 mM phosphate). Light microscopy showed a uniform, cobblestone-shaped monolayer with prominent cilia and brush borders. AT(2) receptor functionality, as demonstrated by angiotensin II inhibition of ANF-stimulated cGMP synthesis, was absent in AT(2)-deficient cells but prominent in wild-type cells. This transport competent cell line in conjunction with corresponding wild type and AT(1)-deficient lines should help explain angiotensin II signaling relevant to Na(+) transport.
Collapse
Affiliation(s)
- Philip G Woost
- Department of Physiology and Biophysics, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4970, USA.
| | | | | | | | | | | |
Collapse
|
216
|
Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest 2007; 117:2496-505. [PMID: 17710229 PMCID: PMC1940235 DOI: 10.1172/jci29838] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2006] [Accepted: 05/29/2007] [Indexed: 11/17/2022] Open
Abstract
Clinical use of prostaglandin synthase-inhibiting NSAIDs is associated with the development of hypertension; however, the cardiovascular effects of antagonists for individual prostaglandin receptors remain uncharacterized. The present studies were aimed at elucidating the role of prostaglandin E2 (PGE2) E-prostanoid receptor subtype 1 (EP1) in regulating blood pressure. Oral administration of the EP1 receptor antagonist SC51322 reduced blood pressure in spontaneously hypertensive rats. To define whether this antihypertensive effect was caused by EP1 receptor inhibition, an EP1-null mouse was generated using a "hit-and-run" strategy that disrupted the gene encoding EP1 but spared expression of protein kinase N (PKN) encoded at the EP1 locus on the antiparallel DNA strand. Selective genetic disruption of the EP1 receptor blunted the acute pressor response to Ang II and reduced chronic Ang II-driven hypertension. SC51322 blunted the constricting effect of Ang II on in vitro-perfused preglomerular renal arterioles and mesenteric arteriolar rings. Similarly, the pressor response to EP1-selective agonists sulprostone and 17-phenyltrinor PGE2 were blunted by SC51322 and in EP1-null mice. These data support the possibility of targeting the EP1 receptor for antihypertensive therapy.
Collapse
Affiliation(s)
- Youfei Guan
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Yahua Zhang
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Jing Wu
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Zhonghua Qi
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Guangrui Yang
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Dou Dou
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Yuansheng Gao
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Lihong Chen
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Xiaoyan Zhang
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Linda S. Davis
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Mingfeng Wei
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Xuefeng Fan
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Monica Carmosino
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Chuanming Hao
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - John D. Imig
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Richard M. Breyer
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Matthew D. Breyer
- Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, People’s Republic of China.
Department of Physiology, Medical College of Georgia, Augusta, Georgia, USA.
Department of Pharmacology and
Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| |
Collapse
|
217
|
Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. ACTA ACUST UNITED AC 2007; 3:486-92. [PMID: 17717561 DOI: 10.1038/ncpneph0575] [Citation(s) in RCA: 282] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2007] [Accepted: 06/13/2007] [Indexed: 02/07/2023]
Abstract
Interruption of the renin-angiotensin-aldosterone system has become a leading therapeutic strategy in the treatment of chronic heart and kidney disease. Angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers do not, however, uniformly suppress the renin-angiotensin-aldosterone system. Plasma aldosterone levels are elevated in a subset of patients despite therapy. This phenomenon, known as 'aldosterone escape' or 'aldosterone breakthrough', has only been directly examined in small numbers of patients. The key questions of how often breakthrough occurs and whether breakthrough leads to worse outcomes have yet to be definitively answered. In this Review, we summarize the reported data on the incidence and clinical implications of aldosterone breakthrough, and highlight areas of uncertainty that have yet to be adequately addressed in the literature. Although the available evidence is not strong enough to support widespread screening for aldosterone breakthrough, our findings should prompt physicians to consider the phenomenon in select patients as well as guide future research efforts.
Collapse
Affiliation(s)
- Andrew S Bomback
- University of North Carolina Kidney Center, Chapel Hill, NC 27599-7155, USA.
| | | |
Collapse
|
218
|
Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, Muffat-Joly M, Escoubet B, Souil E, Hamard G, Bernstein KE, Gasc JM, Elghozi JL, Corvol P, Clauser E. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest 2007; 117:1914-25. [PMID: 17607364 PMCID: PMC1890996 DOI: 10.1172/jci28764] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Accepted: 04/24/2007] [Indexed: 01/06/2023] Open
Abstract
The role of the renin-angiotensin system has been investigated by overexpression or inactivation of its different genes in animals. However, there is no data concerning the effect of the constitutive activation of any component of the system. A knockin mouse model has been constructed with a gain-of-function mutant of the Ang II receptor, type 1A (AT(1A)), associating a constitutively activating mutation (N111S) with a C-terminal deletion, which impairs receptor internalization and desensitization. In vivo consequences of this mutant receptor expression in homozygous mice recapitulate its in vitro characteristics: the pressor response is more sensitive to Ang II and longer lasting. These mice present with a moderate (~20 mmHg) and stable increase in BP. They also develop early and progressive renal fibrosis and cardiac fibrosis and diastolic dysfunction. However, there was no overt cardiac hypertrophy. The hormonal parameters (low-renin and inappropriately normal aldosterone productions) mimic those of low-renin human hypertension. This new model reveals that a constitutive activation of AT(1A) leads to cardiac and renal fibrosis in spite of a modest effect on BP and will be useful for investigating the role of Ang II in target organs in a model similar to some forms of human hypertension.
Collapse
Affiliation(s)
- Sandrine Billet
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sabine Bardin
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sonia Verp
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Véronique Baudrie
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Annie Michaud
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sophie Conchon
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Martine Muffat-Joly
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Brigitte Escoubet
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Evelyne Souil
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ghislaine Hamard
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Kenneth E. Bernstein
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Jean Marie Gasc
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Jean-Luc Elghozi
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Pierre Corvol
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Eric Clauser
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| |
Collapse
|
219
|
Salzler HR, Griffiths R, Ruiz P, Chi L, Frey C, Marchuk DA, Rockman HA, Le TH. Hypertension and albuminuria in chronic kidney disease mapped to a mouse chromosome 11 locus. Kidney Int 2007; 72:1226-32. [PMID: 17851470 PMCID: PMC7185734 DOI: 10.1038/sj.ki.5002519] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Chronic kidney disease (CKD) is a key cause of hypertension and a potent independent risk for cardiovascular disease. Epidemiological studies suggest a strong genetic component determining susceptibility for renal disease and, by inference, the associated cardiovascular risk. With a subtotal nephrectomy model of kidney disease, we found the 129S6 mouse strain to be very susceptible to the development of hypertension, albuminuria, and kidney injury, whereas the C57BL/6 strain is relatively resistant. Accordingly, we set out to map quantitative trait loci conferring susceptibility to hypertension and albuminuria using this model with F2 mice. We found significant linkage of the blood pressure trait to two loci. At D11Mit143, mice homozygous for the 129S6 allele had significantly higher systolic blood pressure than mice heterozygous or homozygous for the C57BL/6 allele. Similarly, at D1Mit308, there was an excellent correlation between genotype and the blood pressure phenotype. The effect of the chromosome 11 locus was verified with a separate cohort of F2 mice. For the albuminuria trait, a significant locus was found at D11Mit143, which overlaps the blood pressure trait locus. Our studies have identified a region spanning approximately 8 cM on mouse chromosome 11 that is associated with susceptibility to hypertension and albuminuria in CKD.
Collapse
Affiliation(s)
- HR Salzler
- Department of Medicine, Duke University, Durham, North Carolina, USA
- Department of Medicine, Durham VA Medical Center, Durham, North Carolina, USA
| | - R Griffiths
- Department of Medicine, Duke University, Durham, North Carolina, USA
- Department of Medicine, Durham VA Medical Center, Durham, North Carolina, USA
| | - P Ruiz
- Department of Pathology, University of Miami, Miami, Florida, USA
| | - L Chi
- Department of Medicine, Duke University, Durham, North Carolina, USA
- Department of Medicine, Durham VA Medical Center, Durham, North Carolina, USA
| | - C Frey
- Department of Medicine, Duke University, Durham, North Carolina, USA
- Department of Medicine, Durham VA Medical Center, Durham, North Carolina, USA
| | - DA Marchuk
- Department of Genetics, Duke University Medical Center, Durham, North Carolina, USA
| | - HA Rockman
- Department of Medicine, Duke University, Durham, North Carolina, USA
| | - TH Le
- Department of Medicine, Duke University, Durham, North Carolina, USA
- Department of Medicine, Durham VA Medical Center, Durham, North Carolina, USA
| |
Collapse
|
220
|
Abstract
The renin-angiotensin system (RAS) is a critical regulator of blood pressure and fluid homeostasis. Components of the RAS, including renin, angiotensin-converting enzyme (ACE), and angiotensin type 1 (AT1) receptors, are expressed throughout the body in tissues that may impact blood pressure control. Blocking actions of individual components of the RAS lowers blood pressure. Although it has been suggested that control of sodium excretion by the kidney is the dominant mechanism for blood pressure regulation by the RAS, pharmacologic antagonists or conventional gene targeting experiments globally interrupt the RAS and cannot discriminate its actions in the kidney from other tissue compartments. Recent experiments using kidney cross-transplantation and genetically engineered mice have confirmed a major role for angiotensin II acting via AT1 receptors in the kidney in hypertension. These actions of renal AT1 receptors are required for the development of angiotensin II-dependent hypertension and cardiac hypertrophy. These findings, with previous experiments, clearly establish the critical role of the kidney in the pathogenesis of hypertension and its cardiovascular complications.
Collapse
|
221
|
Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112:417-28. [PMID: 17346243 DOI: 10.1042/cs20060342] [Citation(s) in RCA: 319] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The intracellular signal transduction of AngII (angiotensin II) has been implicated in cardiovascular diseases, such as hypertension, atherosclerosis and restenosis after injury. AT(1) receptor (AngII type-1 receptor), a G-protein-coupled receptor, mediates most of the physiological and pathophysiological actions of AngII, and this receptor is predominantly expressed in cardiovascular cells, such as VSMCs (vascular smooth muscle cells). AngII activates various signalling molecules, including G-protein-derived second messengers, protein kinases and small G-proteins (Ras, Rho, Rac etc), through the AT(1) receptor leading to vascular remodelling. Growth factor receptors, such as EGFR (epidermal growth factor receptor), have been demonstrated to be 'trans'-activated by the AT(1) receptor in VSMCs to mediate growth and migration. Rho and its effector Rho-kinase/ROCK are also implicated in the pathological cellular actions of AngII in VSMCs. Less is known about the endothelial AngII signalling; however, recent studies suggest the endothelial AngII signalling positively, as well as negatively, regulates the NO (nitric oxide) signalling pathway and, thereby, modulates endothelial dysfunction. Moreover, selective AT(1)-receptor-interacting proteins have recently been identified that potentially regulate AngII signal transduction and their pathogenic functions in the target organs. In this review, we focus our discussion on the recent findings and concepts that suggest the existence of the above-mentioned novel signalling mechanisms whereby AngII mediates the formation of cardiovascular diseases.
Collapse
Affiliation(s)
- Sadaharu Higuchi
- Cardiovascular Research Center, Department of Physiology, Temple University School of Medicine, Philadelphia, PA 19140, USA
| | | | | | | | | | | |
Collapse
|
222
|
Wagner C, de Wit C, Kurtz L, Grünberger C, Kurtz A, Schweda F. Connexin40 is essential for the pressure control of renin synthesis and secretion. Circ Res 2007; 100:556-63. [PMID: 17255527 DOI: 10.1161/01.res.0000258856.19922.45] [Citation(s) in RCA: 166] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Renin secretion and synthesis in renal juxtaglomerular cells are controlled by short feed back loops involving angiotensin II and the intrarenal blood pressure. The operating mechanisms of these negative feed back regulators are widely unknown, except for the fact that both require calcium to exert their inhibitory action. We here show that in the absence of connexin40 (Cx40), which form gap junctions between juxtaglomerular and endothelial cells, the negative control of renin secretion and synthesis by angiotensin II and by intravasal pressure is abrogated, while the regulation by salt intake and beta-adrenergic stimulation is maintained. Renin secretion from Cx40-deficient kidneys or wild-type kidneys treated with the nonselective gap junction blocker 18alpha-glycyrrhetinic acid (10 micromol/L) resembles the situation in wild-type kidneys in the absence of extracellular calcium. This disturbed regulation is reflected by an enhanced plasma renin concentration despite an elevated blood pressure in Cx40-deficient mice. These findings indicate that Cx40 connexins and likely intercellular communication via Cx40-dependent gap junctions mediate the calcium-dependent inhibitor effects of angiotensin II and of intrarenal pressure on renin secretion and synthesis. Because Cx40 gap junctions are also formed between renin producing cells and endothelial cells our finding could provide additional information to suggest that the endothelium may be strongly involved in the control of the renin system.
Collapse
Affiliation(s)
- Charlotte Wagner
- Physiologisches Institut der Universität Regensburg, Regensburg, Germany.
| | | | | | | | | | | |
Collapse
|
223
|
Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007; 292:H2966-72. [PMID: 17293491 DOI: 10.1152/ajpheart.01227.2006] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
In cirrhosis, arterial vasodilatation leads to central hypovolemia and activation of the sympathetic nervous and renin-angiotensin-aldosterone systems. As the liver disease and circulatory dysfunction may affect baroreflex sensitivity (BRS), we assessed BRS in a large group of patients with cirrhosis and in controls who were all supine and some after 60 degrees passive head-up and 30 degrees head-down tilting in relation to central hemodynamics and activity of the sympathetic nervous and renin-angiotensin-aldosterone systems. One-hundred and five patients (Child classes A/B/C: 21/55/29) and 25 (n=11 + 14) controls underwent a full hemodynamic investigation. BRS was assessed by cross-spectral analysis of variabilities between blood pressure and heart rate time series. The median BRS was significantly lower in the supine cirrhotic patients, 3.7 (range 0.3-30.7) ms/mmHg than in matched controls (n=11): 14.3 (6.1-23.6) ms/mmHg, P<0.001. A stepwise multiple-regression analysis revealed that serum sodium (P=0.044), heart rate (P=0.027), and central circulation time (P=0.034) independently correlated with BRS. Head-down tilting had no effects on BRS, but, after head-up tilting, BRS was similar in the patients (n=23) and controls (n=14). In conclusion, BRS is reduced in cirrhosis in the supine position and relates to various aspects of cardiovascular dysfunction, but no further reduction was observed in parallel with the amelioration of the hyperdynamic circulation after head-up tilting. The results indicate that liver dysfunction and compensatory mechanisms to vasodilatation may be involved in the low BRS, which may contribute to poor cardiovascular adaptation in cirrhosis.
Collapse
Affiliation(s)
- Søren Møller
- Department of Clinical Physiology, Hvidovre Hospital, DK-2650 Hvidovre, Denmark.
| | | | | | | |
Collapse
|
224
|
Lawson CR, Doulton TW, MacGregor GA. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2007; 7:139-45. [PMID: 17094050 DOI: 10.3317/jraas.2006.023] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Raised blood pressure (BP) is extremely common in individuals with autosomal dominant polycystic kidney disease (ADPKD) and is almost invariably raised once they develop renal failure. The underlying mechanisms for the rise in BP in individuals with ADPKD are unclear. The progressive number and enlargement of renal cysts, causing structural damage to the kidneys and, thereby, affecting tubular function as well as causing distortion of the glomeruli and renal ischaemia, is likely to be of primary importance. There is some evidence from animal models that there may be over-activity of the intra-renal renin-angiotensin system (RAS) that could account for the rise in BP. Studies in man have shown conflicting results, but a recent more carefully controlled study using both measurements of activity and pharmacological blockade of the RAS clearly demonstrated no evidence of over-activity of the circulating RAS in ADPKD compared to matched individuals with essential hypertension. A more likely explanation for the rise in BP that occurs in ADPKD is retention of sodium and water due to tubular damage. Disappointingly, in spite of good evidence that RAS blocking drugs slow the progression of other renal, particularly glomerular, diseases, there is little evidence to suggest this is true for patients with ADPKD. Nevertheless, there is no doubt that lowering BP in ADPKD is just as important, if not more important, as in essential hypertension to prevent cardiovascular disease and strokes, with a recommended BP target of < 120/80 mmHg.
Collapse
Affiliation(s)
- Catherine R Lawson
- Blood Pressure Unit, Dept of Cardiac & Vascular Sciences, St. George's, University of London, London, UK
| | | | | |
Collapse
|
225
|
Pathophysiology of Hypertension. Hypertension 2007. [DOI: 10.1016/b978-1-4160-3053-9.50009-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
226
|
Abstract
A crosstransplantation study between genetically matched angiotensin AT1 receptor knockout and wild-type mice revealed that renal AT1 receptors are required for the development of angiotensin II-induced hypertension (). However, in this experimental setting, hypertension-related left ventricular hypertrophy seemed to depend on blood pressure elevation rather than on the expression of AT1 receptors in the heart.
Collapse
Affiliation(s)
- Ulrike Muscha Steckelings
- Center for Cardiovascular Research, Institute of Pharmacology, Charité-Universitätsmedizin Berlin, 10115 Berlin, Germany
| | | | | |
Collapse
|
227
|
|
228
|
Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006; 103:17985-90. [PMID: 17090678 PMCID: PMC1693859 DOI: 10.1073/pnas.0605545103] [Citation(s) in RCA: 523] [Impact Index Per Article: 29.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Essential hypertension is a common disease, yet its pathogenesis is not well understood. Altered control of sodium excretion in the kidney may be a key causative feature, but this has been difficult to test experimentally, and recent studies have challenged this hypothesis. Based on the critical role of the renin-angiotensin system (RAS) and the type I (AT1) angiotensin receptor in essential hypertension, we developed an experimental model to separate AT1 receptor pools in the kidney from those in all other tissues. Although actions of the RAS in a variety of target organs have the potential to promote high blood pressure and end-organ damage, we show here that angiotensin II causes hypertension primarily through effects on AT1 receptors in the kidney. We find that renal AT1 receptors are absolutely required for the development of angiotensin II-dependent hypertension and cardiac hypertrophy. When AT1 receptors are eliminated from the kidney, the residual repertoire of systemic, extrarenal AT1 receptors is not sufficient to induce hypertension or cardiac hypertrophy. Our findings demonstrate the critical role of the kidney in the pathogenesis of hypertension and its cardiovascular complications. Further, they suggest that the major mechanism of action of RAS inhibitors in hypertension is attenuation of angiotensin II effects in the kidney.
Collapse
Affiliation(s)
- Steven D. Crowley
- *Department of Medicine, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710
| | - Susan B. Gurley
- *Department of Medicine, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710
| | - Maria J. Herrera
- *Department of Medicine, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710
| | - Phillip Ruiz
- Department of Pathology, University of Miami, Miami, FL 33136; and
| | - Robert Griffiths
- *Department of Medicine, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710
| | - Anil P. Kumar
- *Department of Medicine, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710
| | - Hyung-Suk Kim
- Department of Pathology, University of North Carolina, Chapel Hill, NC 27599
| | - Oliver Smithies
- Department of Pathology, University of North Carolina, Chapel Hill, NC 27599
| | - Thu H. Le
- *Department of Medicine, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710
| | - Thomas M. Coffman
- *Department of Medicine, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710
- To whom correspondence should be addressed at:
Duke University Medical Center, Box 3014, Durham, NC 27710. E-mail:
| |
Collapse
|
229
|
Abstract
Hypertension detected in patients with renovascular disease poses a major clinical challenge. The rapid expansion of noninvasive imaging, effective antihypertensive drug therapy, and endovascular interventional procedures combine to make optimal management a moving target. Renal arterial disease accelerates the development of hypertension associated with activation of multiple pressor systems and accelerated target organ injury. Younger individuals with fibromuscular lesions often respond well to renal revascularization with minor associated risks. Care must be taken in cases of complex vascular anomalies, such as renal artery aneurysms. Atherosclerotic renal artery stenosis is detected more commonly than ever before and affects more than 85% of patients referred for revascularization. Most are older patients with long-standing hypertension, diabetes, and pre-existing complications of vascular disease. The benefits of extensive workup and intervention in this group of patients are controversial. Antihypertensive drug therapy is most effectively achieved with drugs that block the renin-angiotensin system, but most require multiple agents. Selection of patients for renal revascularization in this group is far more controversial than with fibromuscular disease. Several small trials failed to identify major benefits with renal artery angioplasty as compared to closely monitored drug therapy, although crossover rates from medical to interventional arms were high. The Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) seeks to randomly assign subjects with proven, high-grade renal artery lesions to optimal medical management with and without stenting. This important trial employs distal embolic protection to prevent deterioration of renal function. Understanding the optimal role for renal revascularization depends heavily upon the successful conduct of such trials.
Collapse
Affiliation(s)
- Stephen C Textor
- Division of Nephrology and Hypertension, Department of Internal Medicine, 200 First Street, Mayo Clinic, Rochester, MN, 55905-0002, USA.
| |
Collapse
|
230
|
Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV. Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt. Hypertension 2006; 48:286-93. [PMID: 16801484 DOI: 10.1161/01.hyp.0000229907.58470.4c] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Endothelin B receptors in different tissues regulate diverse physiological responses including vasoconstriction, vasodilatation, clearance of endothelin-1, and renal tubular sodium reabsorption. To examine the role of endothelial cell endothelin B receptors in these processes, we generated endothelial cell-specific endothelin B receptor knockout mice using a Cre-
loxP
approach. We have demonstrated loss of endothelial cell endothelin B receptor expression and function and preservation of nonendothelial endothelin B receptor-mediated responses through binding and functional assays. Ablation of endothelin B receptors exclusively from endothelial cells produces endothelial dysfunction in the absence of hypertension, with evidence of decreased endogenous release of NO and increased plasma endothelin-1. In contrast to models of total endothelin B receptor ablation, the blood pressure response to a high-salt diet is unchanged in endothelial cell–specific endothelin B receptor knockouts compared with control floxed mice. These findings suggest that the endothelial cell endothelin B receptor mediates a tonic vasodilator effect and that nonendothelial cell endothelin B receptors are important for the regulation of blood pressure.
Collapse
Affiliation(s)
- Alan J Bagnall
- Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, Little France Crescent, Edinburgh, EH16 4TJ United Kingdom.
| | | | | | | | | | | | | | | |
Collapse
|
231
|
Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116:2218-25. [PMID: 16878172 PMCID: PMC1518789 DOI: 10.1172/jci16980] [Citation(s) in RCA: 259] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2002] [Accepted: 06/06/2006] [Indexed: 12/27/2022] Open
Abstract
The carboxypeptidase ACE2 is a homologue of angiotensin-converting enzyme (ACE). To clarify the physiological roles of ACE2, we generated mice with targeted disruption of the Ace2 gene. ACE2-deficient mice were viable, fertile, and lacked any gross structural abnormalities. We found normal cardiac dimensions and function in ACE2-deficient animals with mixed or inbred genetic backgrounds. On the C57BL/6 background, ACE2 deficiency was associated with a modest increase in blood pressure, whereas the absence of ACE2 had no effect on baseline blood pressures in 129/SvEv mice. After acute Ang II infusion, plasma concentrations of Ang II increased almost 3-fold higher in ACE2-deficient mice than in controls. In a model of Ang II-dependent hypertension, blood pressures were substantially higher in the ACE2-deficient mice than in WT. Severe hypertension in ACE2-deficient mice was associated with exaggerated accumulation of Ang II in the kidney, as determined by MALDI-TOF mass spectrometry. Although the absence of functional ACE2 causes enhanced susceptibility to Ang II-induced hypertension, we found no evidence for a role of ACE2 in the regulation of cardiac structure or function. Our data suggest that ACE2 is a functional component of the renin-angiotensin system, metabolizing Ang II and thereby contributing to regulation of blood pressure.
Collapse
Affiliation(s)
- Susan B. Gurley
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Alicia Allred
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Thu H. Le
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Robert Griffiths
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Lan Mao
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Nisha Philip
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Timothy A. Haystead
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Mary Donoghue
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Roger E. Breitbart
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Susan L. Acton
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Howard A. Rockman
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Thomas M. Coffman
- Division of Nephrology and
Division of Cardiology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina, USA.
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| |
Collapse
|
232
|
Samuelsson AM, Alexanderson C, Mölne J, Haraldsson B, Hansell P, Holmäng A. Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat. J Physiol 2006; 575:855-67. [PMID: 16825309 PMCID: PMC1995698 DOI: 10.1113/jphysiol.2006.111260] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Cytokines are emerging as important in developmental processes. They may induce alterations in normal gene expression patterns, activate angiotensinogen transcription, or alter expression of the renin-angiotensin system (RAS). To determine whether prenatal exposure to interleukin-6 (IL-6) influences gene expression of the intrarenal RAS and contributes to renal dysfunction and hypertension in adulthood, we exposed female rats to IL-6 early (EIL-6 females) and late (LIL-6 females) in pregnancy and analysed blood pressure in the offspring at 5-20 weeks of age. Renal fluid and electrolyte excretion was assessed in clearance experiments, mRNA expression by real-time PCR, and protein levels by Western blot. Systolic pressure was increased at 5 weeks in IL-6 females and at 11 weeks in males. Circulatory RAS levels were increased in all IL-6 females, but angiotensin-1-converting enzyme (ACE) activity was increased only in LIL-6 females. LIL-6 males and IL-6 females showed decreased urinary flow rate and urinary sodium and potassium excretion. Dopamine excretion was decreased IL-6 females. In adult renal cortex, renin expression was increased in all IL-6 females, but angiotensinogen mRNA was increased only in LIL-6 females; AT(1) receptor (AT(1)-R) mRNA and protein levels were increased in LIL-6 females, whereas AT(2) receptor (AT(2)-R) levels were decreased in LIL-6 females and EIL-6 males. In adult renal medulla, AT(1)-R protein levels were increased in LIL-6 females, and AT(2)-R mRNA and protein levels were decreased in EIL-6 males and LIL-6 females. Prenatal IL-6 exposure may cause hypertension by altering the renal and circulatory RAS and renal fluid and electrolyte excretion, especially in females.
Collapse
Affiliation(s)
- Anne-Maj Samuelsson
- Institute of Neuroscience and Physiology, Göteborg University, S-413 45 Göteborg, Sweden.
| | | | | | | | | | | |
Collapse
|
233
|
Abstract
In this review, we outline the application and contribution of transgenic technology to establishing the genetic basis of blood pressure regulation and its dysfunction. Apart from a small number of examples where high blood pressure is the result of single gene mutation, essential hypertension is the sum of interactions between multiple environmental and genetic factors. Candidate genes can be identified by a variety of means including linkage analysis, quantitative trait locus analysis, association studies, and genome-wide scans. To test the validity of candidate genes, it is valuable to model hypertension in laboratory animals. Animal models generated through selective breeding strategies are often complex, and the underlying mechanism of hypertension is not clear. A complementary strategy has been the use of transgenic technology. Here one gene can be selectively, tissue specifically, or developmentally overexpressed, knocked down, or knocked out. Although resulting phenotypes may still be complicated, the underlying genetic perturbation is a starting point for identifying interactions that lead to hypertension. We recognize that the development and maintenance of hypertension may involve many systems including the vascular, cardiac, and central nervous systems. However, given the central role of the kidney in normal and abnormal blood pressure regulation, we intend to limit our review to models with a broadly renal perspective.
Collapse
Affiliation(s)
- Linda J Mullins
- Molecular Physiology Laboratory, Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | | | | |
Collapse
|
234
|
Sanada H, Yatabe J, Midorikawa S, Katoh T, Hashimoto S, Watanabe T, Xu J, Luo Y, Wang X, Zeng C, Armando I, Felder RA, Jose PA. Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression. Hypertension 2006; 47:1131-9. [PMID: 16636192 DOI: 10.1161/01.hyp.0000222004.74872.17] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Abnormalities in D1 dopamine receptor function in the kidney are present in some types of human essential and rodent genetic hypertension. We hypothesize that increased activity of G protein-coupled receptor kinase type 4 (GRK4) causes the impaired renal D1 receptor function in hypertension. We measured renal GRK4 and D1 and serine-phosphorylated D1 receptors and determined the effect of decreasing renal GRK4 protein by the chronic renal cortical interstitial infusion (4 weeks) of GRK4 antisense oligodeoxynucleotides (As-Odns) in conscious- uninephrectomized spontaneously hypertensive rats (SHRs) and their normotensive controls, Wistar-Kyoto (WKY) rats. Basal GRK4 expression and serine-phosphorylated D1 receptors were &90% higher in SHRs than in WKY rats and were decreased to a greater extent in SHRs than in WKY rats with GRK4 As-Odns treatment. Basal renal D1 receptor protein was similar in both rat strains. GRK4 As-Odns, but not scrambled oligodeoxynucleotides, increased sodium excretion and urine volume, attenuated the increase in arterial blood pressure with age, and decreased protein excretion in SHRs, effects that were not observed in WKY rats. These studies provide direct evidence of a crucial role of renal GRK4 in the D1 receptor control of sodium excretion and blood pressure in genetic hypertension.
Collapse
Affiliation(s)
- Hironobu Sanada
- Department of Internal Medicine III, Fukushima Medical University School of Medicine, Fukushima, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
235
|
Wang L, Flannery PJ, Athirakul K, Dunn SR, Kourany WM, Spurney RF. Galphaq-dependent signaling cascades stimulate water-seeking behavior. Am J Physiol Renal Physiol 2006; 291:F781-9. [PMID: 16609148 DOI: 10.1152/ajprenal.00401.2005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We used the mouse nephrin promoter to express a constitutively active Galphaq [Galphaq(Q>L)] transgene in mice. As previously reported, the transgene was expressed in kidney, pancreas, and brain, and the kidney phenotype was characterized by albuminuria and reduced nephron mass. Additional studies revealed a second phenotype characterized by polyuria and polydipsia. The polyuric phenotype was not caused by abnormal glucose metabolism or hypercalcemia but was accompanied by reduced urinary concentrating ability. Additional studies found that 1) water restriction was associated with an appropriate increase in serum vasopressin levels in transgenic (TG) mice; 2) the urinary concentrating defect was not corrected by administration of desamino-d-arginine vasopressin (DDAVP); and 3) papillary length was similar in TG and non-TG mice. To examine the renal response to DDAVP at the molecular level, we monitored aquaporin 2 (AQP2) and vasopressin V2 receptor (V2R) mRNA levels in mouse kidney. Consistent with the known effects of vasopressin, administration of DDAVP caused a decrease in V2R mRNA levels and an increase in AQP2 mRNA levels in both TG and non-TG animals, suggesting an appropriate renal response to DDAVP in the TG mice. To determine whether the urine concentrating abnormality was the result of primary polydipsia, water intake by TG mice was restricted to the amount ingested by non-TG animals. After 5 days, urinary concentrating ability was similar in TG mice and non-TG littermate controls. These data are consistent with the notion that expression of the Galphaq(Q>L) transgene in the brain induced primary polydipsia in the TG mice.
Collapse
Affiliation(s)
- Liming Wang
- Division of Nephrology, Department of Medicine, Duke University, Durham, NC 27710, USA
| | | | | | | | | | | |
Collapse
|
236
|
Goossens GH, McQuaid SE, Dennis AL, van Baak MA, Blaak EE, Frayn KN, Saris WHM, Karpe F. Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol 2006; 571:451-60. [PMID: 16396927 PMCID: PMC1796792 DOI: 10.1113/jphysiol.2005.101352] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
We investigated the functional roles of circulating and locally produced angiotensin II (Ang II) in fasting and postprandial adipose tissue blood flow (ATBF) regulation and examined the interaction between Ang II and nitric oxide (NO) in ATBF regulation. Local effects of the pharmacological agents (or contralateral saline) on ATBF, measured with 133Xe wash-out, were assessed using the recently developed microinfusion technique. Fasting and postprandial (75 g glucose challenge) ATBF regulation was investigated in nine lean healthy subjects (age, 29 +/- 3 years; BMI, 23.4 +/- 0.7 kg m(-2)) using local Ang II stimulation, Ang II type 1 (AT1) receptor blockade, and angiotensin-converting enzyme (ACE) inhibition. Furthermore, NO synthase (NOS) blockade alone and in combination with AT1 receptor blockade was used to examine the interaction between Ang II and NO. Ang II induced a dose-dependent decrease in ATBF (10(-9)m: -16%, P = 0.04; 10(-7)m: -33%, P < 0.01; 10(-5)m: -53%P < 0.01). Fasting ATBF was not affected by ACE inhibition, but was increased by approximately 55% (P < 0.01) by AT(1) receptor blockade. NOS blockade induced a approximately 30% (P = 0.001) decrease in fasting ATBF. Combined AT1 receptor and NOS blockade increased ATBF by approximately 40% (P = 0.003). ACE inhibition and AT1 receptor blockade did not affect the postprandial increase in ATBF. We therefore conclude that circulating Ang II is a major regulator of fasting ATBF, and a major proportion of the Ang II-induced decrease in ATBF is NO independent. Locally produced Ang II does not appear to regulate ATBF. Ang II appears to have no major effect on the postprandial enhancement of ATBF.
Collapse
Affiliation(s)
- G H Goossens
- Department of Human Biology, Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Maastricht University, Maastricht, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
237
|
Siragy HM. Angiotensin II compartmentalization within the kidney: effects of salt diet and blood pressure alterations. Curr Opin Nephrol Hypertens 2006; 15:50-3. [PMID: 16340666 DOI: 10.1097/01.mnh.0000196148.42460.4f] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW All components of the renin-angiotensin-aldosterone system are present within the kidney. Renin, renin receptor, angiotensinogen and angiotensin AT1 and AT2 receptor and aldosterone synthase messenger RNA and protein are present in close proximity to the renal vasculature and tubules. The interaction between the different components of the renin-angiotensin-aldosterone system determines the level of activity of this system and in turn may influence the regulation of blood pressure and renal sodium handling. RECENT FINDINGS Angiotensin through the stimulation of its subtype AT2 receptor regulates sodium excretion, renin synthesis and secretion. Aldosterone synthase mRNA and protein are expressed in glomeruli, renal vasculature and tubules, and are regulated by angiotensin AT1 receptor, diabetes and salt. Although aldosterone is known to influence renal tubular channels with the subsequent enhancement of sodium reabsorption, it is not clear if the renally produced aldosterone also influences renal sodium handling or blood pressure regulation. In addition, angiotensin II influences kidney function and structure through the stimulation of renal inflammation. New data suggest that the renal AT1 receptor plays an important role in the determination of blood pressure levels, and this effect is unique and non-redundant in the actions of extrarenal AT1 receptors. SUMMARY The finding of new functions and components of the renin-angiotensin-aldosterone system clearly adds new knowledge to our understanding of how angiotensin II influences the kidney and blood pressure.
Collapse
Affiliation(s)
- Helmy M Siragy
- Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908-1409, USA.
| |
Collapse
|
238
|
Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 2005; 47:537-44. [PMID: 16380540 DOI: 10.1161/01.hyp.0000196950.48596.21] [Citation(s) in RCA: 116] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Whereas angiotensin (Ang) II is the major effector peptide of the renin-angiotensin system, its metabolite, des-aspartyl1-Ang II (Ang III), may also have biologic activity. We investigated the effects of renal interstitial (RI) administration of candesartan (CAND), a specific Ang II type 1 receptor (AT1) blocker, with and without coinfusion of PD-123319 (PD), a specific Ang II type 2 receptor (AT2) blocker, on Na+ excretion (UNaV) in uninephrectomized rats. We also studied the effects of unilateral RI infusion of Ang II or Ang III on UNaV with and without systemic infusion of CAND with the noninfused kidney as control. In rats receiving normal Na+ intake, RI CAND increased UNaV from 0.07+/-0.08 to 0.82+/-0.17 micromol/min (P<0.01); this response was abolished by PD. During Na+ restriction, CAND increased UNaV from 0.06+/-0.02 to 0.1+/-0.02 micromol/min (P<0.05); this response also was blocked by PD. In rats with both kidneys intact, in the absence of CAND, unilateral RI infusion of Ang III did not significantly alter UNaV. However, with systemic CAND infusion, RI Ang III increased U(Na)V from 0.08+/-0.01 micromol/min to 0.18+/-0.04 micromol/min (P<0.01) at 3.5 nmol/kg per minute, and UNaV remained elevated throughout the infusion; this response was abolished by PD. However, RI infusion of Ang II did not significantly alter UNaV at any infusion rate (3.5 to 80 nmol/kg per minute) with or without systemic CAND infusion. These results suggest that intrarenal AT1 receptor blockade engenders natriuresis by activation of AT2 receptors. AT2 receptor activation via Ang III, but not via Ang II, mediates the natriuretic response in the presence of systemic AT1 receptor blockade.
Collapse
Affiliation(s)
- Shetal H Padia
- Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-1414, USA
| | | | | | | |
Collapse
|
239
|
Affiliation(s)
- Rainer Rettig
- Department of Physiology, University of Greifswald, D-17495 Karlsburg, Germany.
| | | |
Collapse
|
240
|
Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, Fitzgerald GA, Koller BH, Coffman TM. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2005; 2:201-7. [PMID: 16154102 DOI: 10.1016/j.cmet.2005.08.005] [Citation(s) in RCA: 120] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2005] [Revised: 07/01/2005] [Accepted: 08/16/2005] [Indexed: 11/20/2022]
Abstract
Specific inhibitors of COX-2 have been associated with increased risk for cardiovascular complications. These agents reduce prostacyclin (PGI2) without affecting production of thromboxane (Tx) A2. While this abnormal pattern of eicosanoid generation has been implicated in the development of vascular disease associated with COX-2 inhibition, its role in the development of hypertension, the most common cardiovascular complication associated with COX-2 inhibition, is not known. We report here that mice lacking the receptor for PGI2 (IPKOs) develop salt-sensitive hypertension, cardiac hypertrophy, and severe cardiac fibrosis. Coincidental deletion of the TxA2 (TP) receptor does not prevent the development of hypertension, but cardiac hypertrophy is ameliorated and fibrosis is prevented in IPTP double knockouts (DKOs). Thus, deletion of the IP receptor removes a constraint revealing adverse cardiovascular consequences of TxA2. Our data suggest that adjuvant therapy that blocks unrestrained Tx actions might protect against end-organ damage without affecting blood pressure in patients taking COX-2 inhibitors.
Collapse
Affiliation(s)
- Helene Francois
- Department of Medicine, Duke University and Durham VA Medical Centers, Durham, North Carolina 27705
| | | | | | | | | | | | | | | | | | | |
Collapse
|
241
|
Mendelsohn ME. In hypertension, the kidney is not always the heart of the matter. J Clin Invest 2005; 115:840-4. [PMID: 15841174 PMCID: PMC1070434 DOI: 10.1172/jci24806] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Blood pressure abnormalities are thought to originate from intrinsic changes in the kidney, a concept that has been largely unchallenged for more than 4 decades. However, recent molecular, cellular, and transgenic mouse studies support an alternative hypothesis: primary abnormalities in vascular cell function can also directly cause abnormalities of blood pressure. In this issue of the JCI, Crowley and coworkers describe the application of an elegant cross-renal transplant model to type 1A angiotensin (AT(1A)) receptor-deficient mice and their wild-type littermates to explore the relative contributions of renal and extrarenal tissues to the low blood pressure seen in the AT(1A) receptor-deficient animals. Their studies further support the emerging paradigm that primary abnormalities of the vasculature can make unique, nonredundant contributions to blood pressure regulation; the findings have potentially important implications for the ways we diagnose and treat blood pressure diseases in humans.
Collapse
MESH Headings
- Animals
- Blood Vessels/abnormalities
- Blood Vessels/cytology
- Blood Vessels/metabolism
- Humans
- Hypertension/physiopathology
- Kidney/physiology
- Kidney Transplantation
- Mice
- Mice, Transgenic
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- Myocytes, Smooth Muscle/metabolism
- Receptor, Angiotensin, Type 1/genetics
- Receptor, Angiotensin, Type 1/metabolism
Collapse
Affiliation(s)
- Michael E Mendelsohn
- Molecular Cardiology Research Institute, Tufts-New England Medical Center, Boston, Massachusetts, USA
| |
Collapse
|
242
|
Yoneda M, Sanada H, Yatabe J, Midorikawa S, Hashimoto S, Sasaki M, Katoh T, Watanabe T, Andrews PM, Jose PA, Felder RA. Differential effects of angiotensin II type-1 receptor antisense oligonucleotides on renal function in spontaneously hypertensive rats. Hypertension 2005; 46:58-65. [PMID: 15956107 DOI: 10.1161/01.hyp.0000171587.44736.ba] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The effect of selectively decreasing renal angiotensin II type 1 (AT1) receptor expression on renal function and blood pressure has not been determined. Therefore, we studied the consequences of selective renal inhibition of AT1 receptor expression in normotensive Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) in vivo. Vehicle, AT1 receptor antisense oligodeoxynucleotides (AS-ODN), or scrambled oligodeoxynucleotides were infused chronically into the cortex of the remaining kidney of conscious, uninephrectomized WKY and SHR on a 4% NaCl intake. Basal renal cortical membrane AT1 receptor protein was greater in SHR than in WKY. In WKY and SHR, AS-ODN decreased renal but not cardiac AT1 receptors. AT1 receptor AS-ODN treatment increased plasma renin activity to a greater extent in WKY than in SHR. However, plasma angiotensin II and aldosterone were increased by AS-ODN to a similar degree in both rat strains. In SHR, sodium excretion was increased and sodium balance was decreased by AS-ODN but had only a transient ameliorating effect on blood pressure. Urinary protein and glomerular sclerosis were markedly reduced by AS-ODN-treated SHR. In WKY, AS-ODN had no effect on sodium excretion, blood pressure, or renal histology but also modestly decreased proteinuria. The major consequence of decreasing renal AT1 receptor protein in the SHR is a decrease in proteinuria, probably as a result of the amelioration in glomerular pathology but independent of systemic blood pressure and circulating angiotensin II levels.
Collapse
Affiliation(s)
- Minoru Yoneda
- Fukushima Medical University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
243
|
Abstract
Studies of the renin-angiotension system and the effects of pharmacologic blockade have enhanced our understanding of renovascular hypertension. A critical degree of arterial stenosis produces kidney ischemia sufficient to activate this hormonal system, whose actions include vasoconstriction and sodium retention. Accurate clinical evaluation may depend upon recognizing the differences in pathophysiology between "one-kidney" and "two-kidney" forms and the dynamic nature of this condition.
Collapse
|